Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

Haematologica. 2022 Mar 1;107(3):737-739. doi: 10.3324/haematol.2021.278855.

¹ Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
² Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
³ Service d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Hôpital Cochin, Paris.
⁴ Groupe Francophone des Myélodysplasies, Hopital Saint Louis, Paris.
⁵ Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. David.Sallman@moffitt.org.

No abstract available

MeSH terms